title: Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
authors.affiliation: Department of Gastroenterology, Alfred Hospital and Monash University, Melbourne, Vic., Australia.
authors.forename: B
authors.initials: B
authors.lastname: Christensen
authors.affiliation: Department of Gastroenterology, Alfred Hospital and Monash University, Melbourne, Vic., Australia.
authors.forename: M P
authors.initials: MP
authors.lastname: Sparrow
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease; D006801:Humans; D007155:Immunologic Factors; D000069285:Infliximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069285:Infliximab; D000068879:Adalimumab